Fernández-Majada, Vanesa
Welz, Patrick-Simon
Ermolaeva, Maria A.
Schell, Michael
Adam, Alexander
Dietlein, Felix
Komander, David
Büttner, Reinhard
Thomas, Roman K.
Schumacher, Björn
Pasparakis, Manolis http://orcid.org/0000-0002-9870-0966
Article History
Received: 7 January 2016
Accepted: 8 July 2016
First Online: 26 August 2016
Competing interests
: R.K.T. is a co-founder and shareholder of Blackfield AG and New Oncology. R.K.T. has received research grants from AstraZeneca, EOS and Merck KgaA, and has received honoraria from AstraZeneca, Bayer, Blackfield AG/New Oncology, Boehringer Ingelheim, Clovis Oncology, Daiichi-Sankyo, Eli Lilly, Johnson & Johnson, Merck KgaA, MSD, Puma, Roche and Sanofi. D.K. is part of the DUB Alliance that includes Cancer Research Technology and FORMA Therapeutics, and is a consultant for FORMA Therapeutics. The other authors declare no competing financial interest.